Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Madrigal Pharmaceuticals, Inc.

http://www.madrigalpharma.com/

Latest From Madrigal Pharmaceuticals, Inc.

Financing Available For Some, But Not All Biopharma Companies In 2023

Investors, advisors and CEOs at the J.P. Morgan Healthcare Conference and Biotech Showcase were somewhat optimistic about fundraising this year, but noted certain companies may have to call it quits.

Financing Deals

Stock Watch: Tales Of Stock Price Overreactions

Two clinical trial announcements in the same NASH indication separated by almost nine years had very similar stock price reactions despite the known unknowns of NASH remaining unknown.

Stock Watch Companies

Inventiva Revises Phase III NASH Plans For Broader Indication

While plans to obtain accelerated approval of lanifibranor remain unchanged, Inventiva now plans to conduct the confirmatory Phase III in cirrhotic patients, meaning a shorter trial duration and possibly broader label.

Clinical Trials Drug Approval Standards

Intercept Gifts Shareholders With NASH Refiling

Nearly two-and-a-half years after an FDA complete response letter stalled obeticholic acid’s path to the first approval in non-alcoholic steatohepatitis, Intercept refiled its NDA on 23 December.

Complete Response Letters Liver & Hepatic
See All

Company Information

  • Other Names / Subsidiaries
    • Via Pharmaceuticals, Inc.
UsernamePublicRestriction

Register